Sanofi Receives Approval for Phase III Clinical Trial of 21-valent Pneumococcal Polysaccharide Conjugate Vaccine in China - 7x24

7 x 24 Track global technological trends

Hot Topic

Day

News Topic

Sanofi Receives Approval for Phase III Clinical Trial of 21-valent Pneumococcal Polysaccharide Conjugate Vaccine in China

2025-07-18 / Read about 0 minute

Author：小编

The National Medical Products Administration (NMPA) of China has granted approval for clinical research on the 21-valent pneumococcal polysaccharide conjugate vaccine, a collaboration between Sanofi China and SK Bioscience. This vaccine represents a groundbreaking achievement as it is the world's first 20-valent or higher pneumococcal polysaccharide conjugate vaccine specifically designed for infants and young children to enter Phase III clinical trials, following the successful completion of earlier Phase III trials across various global regions.

Previous page：MIIT to Unveil Digital Transformation Blueprints f...

Next page：BP Divests US Onshore Wind Power Operations

Return to List

Hot Reading

2 day ago

Nalini Priya Uppari Established AI DOC Co-pilot at Enterprise Innovation with AI for Governance and Compliance as Her Organization's Core Business Focus

2 day ago

Sustaining AI Performance: Engineering Reliable GPU Systems

1 day ago

Psychiatrists Warn That Talking to AI Is Leading to Severe Mental Health Issues

2 day ago

Evidence Grows That GPT-5 Is a Bit of a Dud